RECEIVED CENTRAL FAX CENTER


FEB 2 3 2006

FAX



Glaxo Wellcome Inc. PO Box 13398 Five Moore Drive Research Triangle Park North Carolina 27709

Tel: 919 483 2100 www.gsk.com



BEST AVAILABLE COPY

Attached:

Amendment Transmittal Supplemental Amendment Certificate of Transmission

The Information contained in these documents is confidential and may also be privileged and is intended for the exclusive use of the addressee designated above. If you are not the intended recipient or the employee or agent responsible to deliver it to the intended recipient, any disclosure, reproduction, distribution, or any other dissemination or use of this communication is strictly prohibited. If you have received this transmission in error please contact us immediately by telephone so that we can arrange for its return.

RECEIVED CENTRAL FAX CENTER NO. 9220 P. 2

AMENDMENT TRANSMITTAL LETTER (Large Entity) Docket No. Applicant(s): Ingold et al. PU4722USW						
Applicant(s). Tagota et al.						
Application No.	Filing Date	Examiner	Customer N	١٥.	Group Art Unit	Confirmation No.
10/505,337	8/23/04	Yong Chu	23347		1626	
Invention: PROCESS FOR PREPARATION OF SUBSTITUTED OXAZOLES/THIAZOLES (as amended) BEST AVAILABLE COPY						
COMMISSIONER FOR PATENTS:						
Transmitted herewith is an amendment in the above-identified application.						
The fee has been calculated and is transmitted as shown below.						
CLAIMS AS AMENDED						
	CLAIMS REMAINING	HIGHEST #	NUMBER EXTRA			ADDITIONAL
	AFTER AMENDMENT	PREV. PAID FOR	CLAIMS PRESENT		RATE	FEE
TOTAL CLAIMS	23 -	23 =	0	×	\$50.00	\$0.00
INDEP. CLAIMS	4 -	4 =	0	×	\$200.00	\$0.00
Multiple Dependent Claims (check if applicable)						\$0.00
TOTAL ADDITIONAL FEE FOR THIS AMENDMENT \$0.00						
 No additional fee is required for amendment. □ Please charge Deposit Account No. in the amount of □ A check in the amount of to cover the filing fee is enclosed. ☑ The Director is hereby authorized to charge payment of the following fees associated with this communication or credit any overpayment to Deposit Account 07-1392 ☑ Any additional filing fees required under 37 C.F.R. 1.16. ☑ Any patent application processing fees under 37 CFR 1.17. □ Payment by credit card. Form PTO-2038. WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038. 						
Attorney for Applicants GlaxoSmithKline Five Moore Drive, PO Box 13398 Research Triangle Park, NC 27709-3398 Telephone: (919) 483-8247 Facsimile: (919) 483-7988 Research Triangle Park						

FEB. 23. 2006 3:16PM GLAXO WELLCOME

Atty. Docket No.: PU4722USW

RECEIVED **CENTRAL FAX CENTER**

NO. 9220 P. 3

FEB 2 3 2006

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Ingold, et al

Serial No.:

10/505,337

Examiner: Yong Chu

Filing Date:

August 23, 2004

Art Unit: 1626

For:

PROCESS FOR PREPARATION OF SUBSTITUTED

OXAZOLES/THIAZOLES (as amended)

Commissioner for Patents Washington D.C. 20231

BEST AVAILABLE COPY

SUPPLEMENTAL AMENDMENT

Sir:

This paper is submitted supplemental to the response filed February 8. 2008. Entry of this supplemental amendment and allowance of the application is earnestly solicited. For the purposes of adding the priority information, amending the title and abstract, please amend the application as follows:

Amendments to the Specification begin on page 2.

Remarks/Arguments begin on page 3.

Abstract begins on page 4. Please substitute the attached Abstract, which has been placed on a separate sheet of paper according to US practice.

PTO/SB/97 (09-04)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Tredemark Officer U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

BEST AVAILABLE COPY

Certificate of Transmission under 37 CFR 1.8

I hereby certify that this correspondence is being facsimile transmitted to the United States Patent and Trademark Office

2/23/06 Allyson K. Jacobs Typed or printed name of person signing Certificate 919-483-9105 Telephone Number Registration Number, if applicable

Note: Each paper must have its own certificate of transmission, or this certificate must identify

This collection of Information is required by 97 CFR 1.8. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 1.8 minutes to complete including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending on the minutes to complete including gathering, preparing, and submitting the complete this form and/or suggestions for reducing this burden, should be sent to individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

each submitted paper.